Identification

Name
Piroxicam
Accession Number
DB00554  (APRD01187)
Type
Small Molecule
Groups
Approved, Investigational
Description

A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. [PubChem]

Structure
Thumb
Synonyms
  • 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxid
  • Piroxicam
  • Piroxicam betadex
  • Piroxicamum
  • Pyroxycam
External IDs
CP-16,171
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Piroxicam Cap 10mgCapsule10 mgOralApotex Corporation1986-12-31Not applicableCanada
Apo Piroxicam Cap 20mgCapsule20 mgOralApotex Corporation1986-12-31Not applicableCanada
FeldeneCapsule20 mg/1OralRemedy Repack2012-09-262016-12-23Us
FeldeneCapsule20 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-25Not applicableUs
FeldeneCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc.1994-05-25Not applicableUs
Feldene Cap 10mgCapsule10 mgOralPfizer1981-12-312002-09-06Canada
Feldene Cap 20mgCapsule20 mgOralPfizer1981-12-312002-07-25Canada
Feldene Sup 10mgSuppository10 mgRectalPfizer1986-12-311999-08-10Canada
Feldene Sup 20mgSuppository20 mgRectalPfizer1986-12-312002-07-25Canada
FexicamSuppository20 mgRectalTechnilab Pharma Inc.1998-08-172004-08-03Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-piroxicam-cap 10mgCapsule10 mgOralAltimed Pharma Inc.1997-09-242004-08-03Canada
Alti-piroxicam-cap 20mgCapsule20 mgOralAltimed Pharma Inc.1995-12-312004-08-03Canada
Dom-piroxicamSuppository10 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
Dom-piroxicamCapsule10 mgOralDominion PharmacalNot applicable2016-10-25Canada
Dom-piroxicamCapsule20 mgOralDominion Pharmacal1999-10-252016-10-25Canada
Dom-piroxicamSuppository20 mgRectalDominion Pharmacal1995-12-312016-10-25Canada
FeldeneCapsule20 mg/1OralKeltman Pharmaceuticals Inc.2007-09-18Not applicableUs
Gen-piroxicam - Cap 20mgCapsule20 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Gen-piroxicam-cap 10mgCapsule10 mgOralGenpharm Ulc1995-12-312010-08-04Canada
Nu-pirox Cap 10mgCapsule10 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TherafeldaminePiroxicam + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-03-032016-10-13Us
International/Other Brands
Bruxicam / Dolonex / Erazon / Feldene / Geldène / Improntal / Roxam (Bosnalijek) / Roxiden / Sasulen / Solocalm / Trast
Categories
UNII
13T4O6VMAM
CAS number
36322-90-4
Weight
Average: 331.346
Monoisotopic: 331.062676609
Chemical Formula
C15H13N3O4S
InChI Key
QYSPLQLAKJAUJT-UHFFFAOYSA-N
InChI
InChI=1S/C15H13N3O4S/c1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h2-9,19H,1H3,(H,16,17,20)
IUPAC Name
4-hydroxy-2-methyl-1,1-dioxo-N-(pyridin-2-yl)-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)NC2=NC=CC=C2)=C(O)C2=C(C=CC=C2)S1(=O)=O

Pharmacology

Indication

For treatment of osteoarthritis and rheumatoid arthritis.

Associated Conditions
Pharmacodynamics

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Piroxicam works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis.

Mechanism of action

The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
Absorption

Well absorbed following oral administration.

Volume of distribution
  • 0.14 L/kg
Protein binding
Not Available
Metabolism

Renal

Route of elimination

Piroxicam and its biotransformation products are excreted in urine and feces, with about twice as much appearing in the urine as in the feces. Approximately 5% of a piroxicam dose is excreted unchanged. However, a substantial portion of piroxicam elimination occurs by hepatic metabolism. Piroxicam is excreted into human milk.

Half life

30 to 86 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Piroxicam Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*3Not Available1075A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Piroxicam.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabPiroxicam may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe serum concentration of Piroxicam can be increased when it is combined with Abiraterone.Approved
AcebutololPiroxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolPiroxicam may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Piroxicam can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Piroxicam.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Piroxicam.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Piroxicam.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.Approved
AliskirenPiroxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Piroxicam.Experimental
AlprenololPiroxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Piroxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Amikacin.Approved, Investigational, Vet Approved
AmiloridePiroxicam may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Piroxicam.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Piroxicam.Approved, Investigational
AncrodPiroxicam may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Piroxicam.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Piroxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Piroxicam.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antipyrine.Approved, Investigational
Antithrombin III humanPiroxicam may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Piroxicam can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanPiroxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Piroxicam.Investigational
ApramycinPiroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Piroxicam.Approved, Investigational
AprepitantThe metabolism of Piroxicam can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinPiroxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinPiroxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanPiroxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololPiroxicam may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapinePiroxicam may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Atamestane.Investigational
AtenololPiroxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Piroxicam.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Piroxicam.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Piroxicam.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Balsalazide.Approved, Investigational
BazedoxifenePiroxicam may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminPiroxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Piroxicam.Approved, Investigational
BefunololPiroxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinPiroxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Piroxicam.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Piroxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Piroxicam.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Piroxicam.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Piroxicam.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Piroxicam.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Piroxicam.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Piroxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololPiroxicam may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Piroxicam.Approved, Investigational
BevantololPiroxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Piroxicam.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
BisoprololPiroxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinPiroxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololPiroxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Piroxicam.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Piroxicam.Investigational
BucindololPiroxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Piroxicam.Approved
BufexamacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bufexamac.Approved, Experimental
BufuralolPiroxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Piroxicam.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Piroxicam.Approved
BupranololPiroxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Piroxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Piroxicam can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Captopril.Approved
CarbamazepineThe metabolism of Piroxicam can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Piroxicam.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Piroxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololPiroxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolPiroxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Piroxicam.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Piroxicam.Approved, Investigational
CeliprololPiroxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Piroxicam can be increased when it is combined with Ceritinib.Approved
CertoparinPiroxicam may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Piroxicam.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
ChlorotrianisenePiroxicam may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Piroxicam.Approved
CholecalciferolThe metabolism of Piroxicam can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cimicoxib.Investigational
CinoxacinPiroxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinPiroxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Piroxicam.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Piroxicam.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Piroxicam.Vet Approved
CloranololPiroxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindionePiroxicam may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Piroxicam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensPiroxicam may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Piroxicam can be decreased when combined with Crisaborole.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Piroxicam.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Piroxicam.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Piroxicam is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilatePiroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Piroxicam can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinPiroxicam may increase the thrombogenic activities of Daidzein.Experimental
DalteparinPiroxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPiroxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Piroxicam.Investigational
DarexabanPiroxicam may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Piroxicam is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Delapril.Investigational
DelavirdineThe metabolism of Piroxicam can be decreased when combined with Delavirdine.Approved
DesipraminePiroxicam may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinPiroxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Piroxicam.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Piroxicam.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Piroxicam.Experimental
DextranPiroxicam may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinPiroxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Piroxicam is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Piroxicam.Approved, Vet Approved
DicoumarolPiroxicam may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolPiroxicam may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolPiroxicam may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Piroxicam.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.Approved
DihydrostreptomycinPiroxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Piroxicam.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Piroxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Piroxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Piroxicam.Approved
DiphenadionePiroxicam may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Piroxicam can be decreased when combined with Dosulepin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Piroxicam.Approved
DrospirenonePiroxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Piroxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Piroxicam.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Piroxicam.Investigational
Edetic AcidPiroxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPiroxicam may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Piroxicam can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Piroxicam is combined with Enalaprilat.Approved
EnoxacinPiroxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinPiroxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Piroxicam.Experimental
EpanololPiroxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolPiroxicam may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Piroxicam.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Piroxicam.Experimental
EplerenonePiroxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Piroxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Equilin.Approved
EquolPiroxicam may increase the thrombogenic activities of Equol.Investigational
EsatenololPiroxicam may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Piroxicam.Approved, Investigational
EsmololPiroxicam may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe excretion of Estradiol can be decreased when combined with Piroxicam.Approved, Investigational, Vet Approved
Estradiol acetatePiroxicam may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionatePiroxicam may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valeratePiroxicam may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolPiroxicam may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedPiroxicam may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piroxicam.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Piroxicam.Experimental
Ethyl biscoumacetatePiroxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Piroxicam.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Piroxicam.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Piroxicam can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Piroxicam.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Piroxicam.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Piroxicam.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Piroxicam.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Piroxicam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Piroxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Piroxicam.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Piroxicam.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Piroxicam.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Piroxicam.Approved, Investigational
FleroxacinPiroxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Piroxicam.Approved, Withdrawn
FloxuridineThe metabolism of Piroxicam can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Piroxicam can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fludrocortisone.Approved, Investigational
FluindionePiroxicam may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequinePiroxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Piroxicam.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Piroxicam.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluorometholone.Approved, Investigational
FluorouracilThe metabolism of Piroxicam can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Piroxicam.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Piroxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Piroxicam.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Piroxicam.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Piroxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxPiroxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Piroxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Piroxicam can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinPiroxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
GabexatePiroxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinPiroxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinPiroxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Piroxicam.Approved, Withdrawn
GemfibrozilThe metabolism of Piroxicam can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPiroxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinPiroxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinPiroxicam may increase the thrombogenic activities of Genistein.Investigational
GentamicinPiroxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1APiroxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Piroxicam.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Piroxicam.Approved
GrepafloxacinPiroxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Piroxicam.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Piroxicam.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Piroxicam is combined with HE3286.Investigational
HeparinPiroxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolPiroxicam may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Piroxicam.Investigational
HydralazinePiroxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Piroxicam.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Piroxicam.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Piroxicam.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
Hygromycin BPiroxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Piroxicam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Piroxicam.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Piroxicam is combined with Icosapent.Approved, Nutraceutical
IdraparinuxPiroxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Piroxicam.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Piroxicam.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Piroxicam.Approved
IndenololPiroxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Piroxicam can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Piroxicam.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Piroxicam.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Piroxicam.Withdrawn
IrbesartanThe metabolism of Piroxicam can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinPiroxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Piroxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Piroxicam.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Piroxicam is combined with Istaroxime.Investigational
KanamycinPiroxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Piroxicam.Experimental
KetoconazoleThe metabolism of Piroxicam can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.Approved
LabetalolPiroxicam may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
LandiololPiroxicam may decrease the antihypertensive activities of Landiolol.Investigational
LapatinibThe metabolism of Piroxicam can be decreased when combined with Lapatinib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Piroxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Piroxicam.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Piroxicam.Approved, Investigational
LepirudinPiroxicam may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
LetaxabanPiroxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololPiroxicam may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololPiroxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinPiroxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Piroxicam.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Piroxicam.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Piroxicam.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Piroxicam.Experimental
LobeglitazoneThe metabolism of Piroxicam can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinPiroxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Piroxicam.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Piroxicam.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Loteprednol.Approved
LovastatinThe metabolism of Piroxicam can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Piroxicam.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Piroxicam.Approved, Investigational
LumacaftorThe serum concentration of Piroxicam can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Piroxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Piroxicam.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Piroxicam.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Piroxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mefenamic acid.Approved
MelagatranPiroxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meloxicam.Approved, Vet Approved
MepindololPiroxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Piroxicam.Approved
MestranolPiroxicam may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Piroxicam.Approved, Investigational, Withdrawn
MethallenestrilPiroxicam may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Piroxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Piroxicam.Approved
Methyl salicylateThe therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Piroxicam.Approved, Vet Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Piroxicam.Approved, Vet Approved
MetipranololPiroxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.Approved
MetoprololPiroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Piroxicam.Investigational, Withdrawn
MiconazoleThe metabolism of Piroxicam can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinPiroxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Piroxicam can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Piroxicam.Approved, Experimental
MifepristoneThe serum concentration of Piroxicam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Piroxicam.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Piroxicam.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Piroxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Piroxicam.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Piroxicam.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Piroxicam.Approved
MoxestrolPiroxicam may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinPiroxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Piroxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Piroxicam.Approved
NabiloneThe metabolism of Piroxicam can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Piroxicam.Approved
NadololPiroxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinPiroxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Piroxicam.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Piroxicam.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Piroxicam.Investigational
Nalidixic AcidPiroxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Piroxicam is combined with NCX 1022.Investigational
NeaminePiroxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololPiroxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Piroxicam.Approved, Withdrawn
NemonoxacinPiroxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Piroxicam.Approved, Investigational
NetilmicinPiroxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Piroxicam can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Piroxicam.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Piroxicam.Experimental
NilotinibThe metabolism of Piroxicam can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Piroxicam.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Piroxicam.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Piroxicam.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Piroxicam.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Piroxicam.Investigational
NorfloxacinPiroxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinPiroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Piroxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Piroxicam.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Piroxicam.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Piroxicam is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Piroxicam is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Piroxicam.Vet Approved
OtamixabanPiroxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.Approved
Oxolinic acidPiroxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololPiroxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Piroxicam.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Piroxicam.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Piroxicam is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Piroxicam.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Piroxicam.Approved, Investigational
PazufloxacinPiroxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinPiroxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPiroxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitratePiroxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfatePiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Perindopril.Approved
PhenindionePiroxicam may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Piroxicam can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonPiroxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Piroxicam can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Piroxicam.Approved, Investigational
PindololPiroxicam may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Piroxicam can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidPiroxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Piroxicam.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Piroxicam.Approved, Investigational
Piromidic acidPiroxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Piroxicam.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorPiroxicam may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinPiroxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphatePiroxicam may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Piroxicam.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pomalidomide.Approved
Potassium CitratePiroxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololPiroxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Piroxicam.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Piroxicam.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Piroxicam.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pregnenolone.Approved, Experimental, Investigational
PrimidoneThe metabolism of Piroxicam can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Piroxicam can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Piroxicam.Experimental
PromestrienePiroxicam may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Piroxicam.Approved, Investigational
PropafenonePiroxicam may decrease the antihypertensive activities of Propafenone.Approved
PropranololPiroxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Piroxicam.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Piroxicam.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Piroxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Piroxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Piroxicam.Vet Approved
Protein CPiroxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanPiroxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePiroxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinPiroxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Piroxicam.Investigational
PuromycinPiroxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Piroxicam can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Quinapril.Approved, Investigational
QuinestrolPiroxicam may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Piroxicam.Approved
QuinineThe metabolism of Piroxicam can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Piroxicam can be decreased when combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinPiroxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinPiroxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Piroxicam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Piroxicam can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.Approved, Investigational
RivaroxabanPiroxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Piroxicam.Approved, Investigational, Withdrawn
RosoxacinPiroxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Piroxicam can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinPiroxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Piroxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Piroxicam.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Piroxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Piroxicam.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Piroxicam.Approved, Investigational
SecobarbitalThe metabolism of Piroxicam can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolPiroxicam may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Piroxicam.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Piroxicam.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Piroxicam.Investigational
SertralineSertraline may increase the antiplatelet activities of Piroxicam.Approved
SildenafilThe metabolism of Piroxicam can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinPiroxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinPiroxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Piroxicam.Approved
SorafenibThe metabolism of Piroxicam can be decreased when combined with Sorafenib.Approved, Investigational
SotalolPiroxicam may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinPiroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Piroxicam.Investigational
StreptomycinPiroxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Piroxicam can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulindac.Approved, Investigational
SulodexidePiroxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Piroxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Piroxicam is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Piroxicam.Experimental
Synthetic Conjugated Estrogens, APiroxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BPiroxicam may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusPiroxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Piroxicam.Approved
TalinololPiroxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Piroxicam.Approved
TamoxifenThe metabolism of Piroxicam can be decreased when combined with Tamoxifen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Piroxicam.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Piroxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Piroxicam.Approved, Investigational
TemafloxacinPiroxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Piroxicam.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Piroxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Piroxicam.Vet Approved
TerbutalinePiroxicam may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Piroxicam.Approved
TertatololPiroxicam may decrease the antihypertensive activities of Tertatolol.Experimental
TetracyclineThe excretion of Tetracycline can be decreased when combined with Piroxicam.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Piroxicam.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiaprofenic acid.Approved
TibolonePiroxicam may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Piroxicam can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Piroxicam can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololPiroxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Piroxicam.Investigational
TioclomarolPiroxicam may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tixocortol.Approved, Withdrawn
TobramycinPiroxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Piroxicam can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Piroxicam.Approved
TopiroxostatThe metabolism of Piroxicam can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Piroxicam.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Piroxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Piroxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Piroxicam is combined with Triamcinolone.Approved, Vet Approved
TriamterenePiroxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Piroxicam.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Piroxicam.Approved, Vet Approved
TrimethoprimThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Piroxicam.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trolamine salicylate.Approved
TrovafloxacinPiroxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinPiroxicam may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Piroxicam.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Piroxicam is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Piroxicam can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Piroxicam can be decreased when combined with Valsartan.Approved, Investigational
VancomycinPiroxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VemurafenibThe serum concentration of Piroxicam can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Piroxicam.Approved
VoriconazoleThe metabolism of Piroxicam can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinPiroxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPiroxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Piroxicam can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Piroxicam.Approved, Investigational
ZeranolPiroxicam may increase the thrombogenic activities of Zeranol.Vet Approved
ZidovudineThe excretion of Zidovudine can be decreased when combined with Piroxicam.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Piroxicam.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Piroxicam.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Piroxicam is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Piroxicam.Withdrawn
Food Interactions
  • Take with food. Avoid alcohol.

References

Synthesis Reference

Paul D. Weeks, "3-Hydroxy 2-methyl benzisothiazolines as intermediates in production of piroxicam." U.S. Patent US4376204, issued April, 1982.

US4376204
General References
Not Available
External Links
Human Metabolome Database
HMDB0014694
KEGG Drug
D00127
KEGG Compound
C01608
PubChem Compound
54676228
PubChem Substance
46505225
ChemSpider
10442653
BindingDB
85245
ChEBI
8249
ChEMBL
CHEMBL527
Therapeutic Targets Database
DAP000181
PharmGKB
PA450985
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Piroxicam
ATC Codes
S01BC06 — PiroxicamM02AA07 — PiroxicamM01AC01 — Piroxicam
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (74.3 KB)
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingPreventionPulpitis - Irreversible1
1, 2RecruitingTreatmentRenal Colic1
2CompletedNot AvailablePostcoital Contraception1
2CompletedTreatmentKnee Osteoarthritis (Knee OA)1
2, 3Not Yet RecruitingTreatmentEmergency Contraception1
4CompletedSupportive CareCytochrome P450 CYP2C9 Enzyme Deficiency / Impacted Third Molar Tooth / Other Surgical Procedures / Pain1
4CompletedTreatmentDysmenorrhea1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentPrimary Dysmenorrhoea1
Not AvailableCompletedDiagnosticDermatitis, Photocontact1

Pharmacoeconomics

Manufacturers
  • Akorn inc
  • Pfizer laboratories div pfizer inc
  • Egis pharmaceuticals
  • Genpharm pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nostrum laboratories inc
  • Roxane laboratories inc
  • Scs pharmaceuticals
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Egis Pharmaceuticals Public Ltd. Co.
  • Goldline Laboratories Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Mepha Ltd.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nostrum Laboratories Inc.
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Pack Pharmaceuticals
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Qualitest
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Va Cmop Dallas
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral20 mg
SuppositoryRectal10 mg
SuppositoryRectal20 mg
CapsuleOral10 mg/1
CapsuleOral20 mg/1
TabletOral10 mg
Kit
Prices
Unit descriptionCostUnit
Piroxicam powder13.16USD g
Akten 3.5% drops7.5USD ml
Feldene 20 mg capsule4.93USD capsule
Feldene 10 mg capsule2.82USD capsule
Piroxicam 20 mg capsule2.69USD capsule
Pms-Piroxicam 20 mg Suppository1.82USD suppository
Piroxicam 10 mg capsule1.44USD capsule
Apo-Piroxicam 20 mg Capsule0.75USD capsule
Novo-Pirocam 20 mg Capsule0.75USD capsule
Nu-Pirox 20 mg Capsule0.75USD capsule
Apo-Piroxicam 10 mg Capsule0.43USD capsule
Gen-Piroxicam 10 mg Capsule0.43USD capsule
Novo-Pirocam 10 mg Capsule0.43USD capsule
Nu-Pirox 10 mg Capsule0.43USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)198-200 °CPhysProp
water solubility23 mg/L (at 22 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.06AVDEEF,A (1997)
logS-4.16ADME Research, USCD
Caco2 permeability-4.45ADME Research, USCD
pKa6.3SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.143 mg/mLALOGPS
logP2.2ALOGPS
logP0.6ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.76ChemAxon
pKa (Strongest Basic)3.79ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity87.04 m3·mol-1ChemAxon
Polarizability32.27 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9898
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5786
P-glycoprotein inhibitor INon-inhibitor0.7285
P-glycoprotein inhibitor IINon-inhibitor0.7453
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateSubstrate0.6437
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7356
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.9086
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8789
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8709
Ames testNon AMES toxic0.8767
CarcinogenicityNon-carcinogens0.7612
BiodegradationNot ready biodegradable0.923
Rat acute toxicity3.1545 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.8311
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0019000000-0d247806d6203409cc16
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014j-0591000000-7d11d429795ac27fa093
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000t-0910000000-42d97ebe5da8190aa202
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001m-2900000000-32c34cd63ced296fee89
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00kf-5900000000-1d4473d813b920140b81
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00lr-0009000000-9e65aa6e4b407ea80734
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000f-3984000000-e855ded4bfe08c600884
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-007c-3900000000-fb37337024398fe8044d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-006t-9600000000-db1bff24de3a9b89b68d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00r2-9200000000-22caea8b3219419be51f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-01vk-6900000000-a75ce07d3bc58c9e773b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-5829000000-bfa87ed6f54b64fe3942
MS/MS Spectrum - , positiveLC-MS/MSsplash10-1000-1698000000-9bfc929b8cee2ec1d841
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-6911100000-64e355e5e08c884173b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Alpha amino acids and derivatives / Pyridines and derivatives / Organosulfonamides / 1,2-thiazines / Benzenoids / Imidolactams / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Carboximidic acids
show 6 more
Substituents
Alpha-amino acid or derivatives / Benzothiazine / Ortho-thiazine / Pyridine / Organosulfonic acid amide / Benzenoid / Imidolactam / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, pyridines, benzothiazine (CHEBI:8249)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Blanco FJ, Guitian R, Moreno J, de Toro FJ, Galdo F: Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999 Jun;26(6):1366-73. [PubMed:10381057]
  2. Bugajski J, Glod R, Gadek-Michalska A, Bugajski AJ: Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion. J Physiol Pharmacol. 2001 Dec;52(4 Pt 2):795-809. [PubMed:11785774]
  3. Fackovcova D, Kristova V, Kriska M: Renal damage induced by the treatment with non-opioid analgesics--theoretical assumption or clinical significance. Bratisl Lek Listy. 2000;101(8):417-22. [PubMed:11153163]
  4. Raju J, Bird RP: Differential modulation of transforming growth factor-betas and cyclooxygenases in the platelet lysates of male F344 rats by dietary lipids and piroxicam. Mol Cell Biochem. 2002 Feb;231(1-2):139-46. [PubMed:11952155]
  5. Veiga AP, Duarte ID, Avila MN, da Motta PG, Tatsuo MA, Francischi JN: Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life Sci. 2004 Oct 22;75(23):2807-17. [PubMed:15464832]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]
  2. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  3. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  4. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563]
  5. Tsuda M, Sekine T, Takeda M, Cha SH, Kanai Y, Kimura M, Endou H: Transport of ochratoxin A by renal multispecific organic anion transporter 1. J Pharmacol Exp Ther. 1999 Jun;289(3):1301-5. [PubMed:10336520]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
  3. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, Endou H: Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):64-75. [PubMed:12063169]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002 Aug;302(2):666-71. [PubMed:12130730]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:22